Prilocaine

Identification

Summary

Prilocaine is a local anesthetic used in dental procedures.

Brand Names

Agoneaze, Anodyne Lpt, Citanest, Citanest Forte, Dermacinrx Prikaan, Emla, Fortacin, Lido Bdk, Lido-prilo Caine Pack, Lidopril, Oraqix, Prilolid, Prizotral, Relador

Generic Name

Prilocaine

DrugBank Accession Number

DB00750

Background

A local anesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165)

Type

Small Molecule

Groups

Approved

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Prilocaine (DB00750)

×

Close

Weight

Average: 220.3107
Monoisotopic: 220.157563272

Chemical Formula

C₁₃H₂₀N₂O

Synonyms

• 2-(Propylamino)-o-propionotoluidide
• 2-Methyl-alpha-propylaminopropionanilide
• alpha-n-Propylamino-2-methylpropionanilide
• N-(2-Methylphenyl)-2-(propylamino)propanamide
• o-Methyl-2-propylaminopropionanilide
• o-Methyl-alpha-propylaminopropionanilide
• Prilocain
• Prilocaina
• Prilocaïne
• Prilocaine
• Prilocaine base
• Prilocainum
• Propitocaine

External IDs

• ASTRA 1512
• ASTRA 1515
• ASTRA-1512
• ASTRA-1515
• L 67

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Used as a local anaesthetic and is often used in dentistry.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Therapies

• Local Anaesthesia therapy

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Prilocaine binds to the intracellular surface of sodium channels which blocks the subsequent influx of sodium into the cell. Action potential propagation and never function is, therefore, prevented. This block is reversible and when the drug diffuses away from the cell, sodium channel function is restored and nerve propagation returns.

Mechanism of action

Prilocaine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers.

Target	Actions	Organism
ASodium channel protein type 5 subunit alpha	inhibitor	Humans

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Prilocaine is 55% protein bound in plasma at a concentraion of 0.5-1.0 mg/mL.¹

Metabolism

Not Available

Route of elimination

Prilocaine is metabolized in both the liver and the kidney and excreted via the kidney.

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Pathway	Category
Prilocaine Action Pathway	Drug action

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Glucose-6-phosphate 1-dehydrogenase	Villeurbanne	Not Available	1000_1002delACC	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Torun	Not Available	1006A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Sunderland	Not Available	105_107delCAT	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Iwatsuki	Not Available	1081G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Serres	Not Available	1082C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Tondela	Not Available	1084_1101delCTGAACGAGCGCAAGGCC	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Loma Linda	Not Available	1089C->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Aachen	Not Available	1089C->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Tenri	Not Available	1096A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Montpellier	Not Available	1132G>A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Calvo Mackenna	Not Available	1138A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Riley	Not Available	1139T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Olomouc	Not Available	1141T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Tomah	Not Available	1153T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Lynwood	Not Available	1154G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Madrid	Not Available	1155C->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Iowa, Walter Reed, Springfield	Not Available	1156A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Beverly Hills, Genova, Iwate, Niigata, Yamaguchi	Not Available	1160G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Hartford	Not Available	1162A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Praha	Not Available	1166A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Krakow	Not Available	1175T>C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Wisconsin	Not Available	1177C->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Nashville, Anaheim, Portici	Not Available	1178G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Alhambra	Not Available	1180G->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Bari	Not Available	1187C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Puerto Limon	Not Available	1192G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Covao do Lobo	Not Available	1205C>A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Clinic	Not Available	1215G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Utrecht	Not Available	1225C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Suwalki	Not Available	1226C->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Riverside	Not Available	1228G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Japan, Shinagawa	Not Available	1229G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kawasaki	Not Available	1229G->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Munich	Not Available	1231A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Georgia	Not Available	1284C->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Sumare	Not Available	1292T->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Telti/Kobe	Not Available	1318C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Santiago de Cuba, Morioka	Not Available	1339G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Harima	Not Available	1358T->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Figuera da Foz	Not Available	1366G->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Amiens	Not Available	1367A>T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Bangkok Noi	Not Available	1376G->T, 1502T->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Fukaya	Not Available	1462G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Campinas	Not Available	1463G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Buenos Aires	Not Available	1465C>T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Arakawa	Not Available	1466C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Brighton	Not Available	1488_1490delGAA	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kozukata	Not Available	159G->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Amsterdam	Not Available	180_182delTCT	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	No name	Not Available	202G->A, 376A->G, 1264C>G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Swansea	Not Available	224T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Urayasu	Not Available	281_283delAGA	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Vancouver	Not Available	317C->G544C->T592C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Mt Sinai	Not Available	376A->G, 1159C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Plymouth	Not Available	488G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Volendam	Not Available	514C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Shinshu	Not Available	527A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Chikugo	Not Available	535A->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Tsukui	Not Available	561_563delCTC	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Pedoplis-Ckaro	Not Available	573C>G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Santiago	Not Available	593G->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Minnesota, Marion, Gastonia, LeJeune	Not Available	637G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Cincinnati	Not Available	637G->T, 1037A->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Harilaou	Not Available	648T->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	North Dallas	Not Available	683_685delACA	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Asahikawa	Not Available	695G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Durham	Not Available	713A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Stonybrook	Not Available	724_729delGGCACT	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Wayne	Not Available	769C->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Aveiro	Not Available	806G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Cleveland Corum	Not Available	820G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Lille	Not Available	821A>T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Bangkok	Not Available	825G>C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Sugao	Not Available	826C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	La Jolla	Not Available	832T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Wexham	Not Available	833C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Piotrkow	Not Available	851T>C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	West Virginia	Not Available	910G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Omiya	Not Available	921G->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Nara	Not Available	953_976delCCACCAAAGGGTACCTGGAC GACC	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Manhattan	Not Available	962G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Rehevot	Not Available	964T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Honiara	Not Available	99A->G / 1360C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Tokyo, Fukushima	Not Available	1246G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Chatham	Not Available	1003G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Fushan	Not Available	1004C->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Partenope	Not Available	1052G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Ierapetra	Not Available	1057C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Anadia	Not Available	1193A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Abeno	Not Available	1220A->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Surabaya	Not Available	1291G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Pawnee	Not Available	1316G->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	S. Antioco	Not Available	1342A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Cassano	Not Available	1347G->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Hermoupolis	Not Available	1347G->C / 1360C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Union,Maewo, Chinese-2, Kalo	Not Available	1360C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Andalus	Not Available	1361G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Cosenza	Not Available	1376G->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Canton, Taiwan- Hakka, Gifu-like, Agrigento-like	Not Available	1376G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Flores	Not Available	1387C->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kaiping, Anant, Dhon, Sapporo-like, Wosera	Not Available	1388G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kamogawa	Not Available	169C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Costanzo	Not Available	179T>C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Amazonia	Not Available	185C->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Songklanagarind	Not Available	196T->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Hechi	Not Available	202G->A / 871G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Namouru	Not Available	208T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Bao Loc	Not Available	352T>C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Crispim	Not Available	375G->T, 379G->T383T->C384C>T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Acrokorinthos	Not Available	376A->G / 463C->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Santa Maria	Not Available	376A->G / 542A->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Ananindeua	Not Available	376A->G / 871G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Vanua Lava	Not Available	383T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Valladolid	Not Available	406C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Belem	Not Available	409C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Liuzhou	Not Available	442G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Shenzen	Not Available	473G>A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Taipei “Chinese- 3”	Not Available	493A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Toledo	Not Available	496C>T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Naone	Not Available	497G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Nankang	Not Available	517T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Miaoli	Not Available	519C->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Mediterranean, Dallas, Panama‚ Sassari, Cagliari, Birmingham	Not Available	563C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Coimbra Shunde	Not Available	592C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Nilgiri	Not Available	593G>A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Radlowo	Not Available	679C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Roubaix	Not Available	811G>C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Haikou	Not Available	835A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Chinese-1	Not Available	835A->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Mizushima	Not Available	848A>G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Osaka	Not Available	853C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Viangchan, Jammu	Not Available	871G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Seoul	Not Available	916G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Ludhiana	Not Available	929G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Farroupilha	Not Available	977C->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Chinese-5	Not Available	1024C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Rignano	Not Available	130G>A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Orissa	Not Available	131C->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	G6PDNice	Not Available	1380G>C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kamiube, Keelung	Not Available	1387C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Neapolis	Not Available	1400C->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Aures	Not Available	143T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Split	Not Available	1442C->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kambos	Not Available	148C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Palestrina	Not Available	170G>A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Metaponto	Not Available	172G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Musashino	Not Available	185C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Asahi	Not Available	202G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	A- (202), Ferrara I	Not Available	202G->A / 376A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Murcia Oristano	Not Available	209A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Ube Konan	Not Available	241C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Lagosanto	Not Available	242G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Guangzhou	Not Available	274C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Hammersmith	Not Available	323T->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Sinnai	Not Available	34G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	A- (680)	Not Available	376A->G / 680G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	A- (968), Betica,Selma, Guantanamo	Not Available	376A->G / 968T->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Salerno Pyrgos	Not Available	383T>G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Quing Yan	Not Available	392G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Lages	Not Available	40G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Ilesha	Not Available	466G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Mahidol	Not Available	487G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Malaga	Not Available	542A->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Sibari	Not Available	634A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Mexico City	Not Available	680G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Nanning	Not Available	703C->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Seattle, Lodi, Modena, Ferrara II, Athens-like	Not Available	844G->C	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Bajo Maumere	Not Available	844G->T	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Montalbano	Not Available	854G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kalyan-Kerala, Jamnaga, Rohini	Not Available	949G->A	ADR Inferred	Increased risk of Methemoglobinemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Gaohe	Not Available	95A->G	ADR Inferred	Increased risk of Methemoglobinemia.	Details
NADH-cytochrome b5 reductase 3	---	Not Available	Exon 2 c.129C>A / Exon 2 c.149G>A  … show all	ADR Inferred	Increased risk of Methemoglobinemia.	Details

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of CNS depression can be increased when Prilocaine is combined with 1,2-Benzodiazepine.
Abemaciclib	The risk or severity of methemoglobinemia can be increased when Abemaciclib is combined with Prilocaine.
Abiraterone	The risk or severity of methemoglobinemia can be increased when Abiraterone is combined with Prilocaine.
Acetaminophen	The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Prilocaine.
Acetazolamide	The risk or severity of methemoglobinemia can be increased when Acetazolamide is combined with Prilocaine.

Food Interactions

• Take separate from meals. This is only required when prilocaine is used in the mouth, as it may cause numbness, which can cause bite injury when eating.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Prilocaine hydrochloride	MJW015BAPH	1786-81-8	BJPJNTKRKALCPP-UHFFFAOYSA-N

International/Other Brands

Citanest (AstraZeneca) / Prilotekal (Goldshield) / Takipril (Meduna) / Xylonest (AstraZeneca)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
4% Citanest Plain Dental	Solution	40 mg / mL	Infiltration	Dentsply Pharmaceutical	2015-12-23	Not applicable
Citanest Plain	Injection, solution	40 mg/1mL	Dental	Dentsply Pharmaceutical	2007-03-02	2007-03-02
Dentsply 4% Prilocaine Hydrochloride Dental Injection	Solution	40 mg / mL	Infiltration	Dentsply Pharmaceutical	1964-12-31	2016-06-03
Truemed Group LLC	Injection	54 mg/54mg	Intramuscular	Truemed Group LLC	2022-09-17	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Citanest Plain	Injection, solution	40 mg/1mL	Submucosal	Dentsply Pharmaceutical Inc.	1965-11-18	Not applicable
Prilocaine Hydrochloride	Injection, solution	40 mg/1mL	Subcutaneous	Septodont	2011-01-01	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
4% Citanest Forte Dental With Epinephrine 1:200,000	Prilocaine hydrochloride (40 mg / mL) + Epinephrine (0.005 mg / mL)	Solution	Infiltration	Dentsply Pharmaceutical	2011-01-18	Not applicable
ANESDERM	Prilocaine (25 MG/G) + Lidocaine (25 MG/G)	Cream	Cutaneous	Pierre Fabre Italia S.P.A.	2015-12-23	Not applicable
ANESDERM	Prilocaine (25 MG/G) + Lidocaine (25 MG/G)	Cream	Cutaneous	Pierre Fabre Italia S.P.A.	2015-12-23	Not applicable
ANESDERM	Prilocaine (25 MG/G) + Lidocaine (25 MG/G)	Cream	Cutaneous	Pierre Fabre Italia S.P.A.	2015-12-23	Not applicable
Anodyne LPT	Prilocaine (25 mg/1g) + Lidocaine (25 mg/1g)	Kit	Topical	Fortus Pharma, Llc	2017-03-22	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
ACAT SUK Kit (Accelerated COVID-19 Antibody Test Single Use Kit)	Prilocaine (25 mg/1g) + Isopropyl alcohol (70 mL/100mL) + Lidocaine (25 mg/1g)	Kit	Topical	Asclemed Usa, Inc.	2020-04-25	Not applicable
ACT Kit (Accelerated COVID-19 Test Kit)	Prilocaine (25 mg/1g) + Isopropyl alcohol (70 mL/100mL) + Lidocaine (25 mg/1g)	Kit	Topical	Asclemed Usa, Inc.	2020-04-13	Not applicable
AgonEaze	Prilocaine (25 mg/1g) + Prilocaine (25 mg/1g) + Lidocaine (25 mg/1g) + Lidocaine (25 mg/1g)	Kit	Topical	Alvix Laboratories	2016-01-12	Not applicable
AgonEaze	Prilocaine (25 mg/1g) + Prilocaine (25 mg/1g) + Lidocaine (25 mg/1g) + Lidocaine (25 mg/1g)	Kit	Topical	Alvix Laboratories	2016-01-12	Not applicable
Aprizio Pak	Prilocaine (25 mg/1g) + Lidocaine (25 mg/1g)	Kit	Topical	PureTek Corporation	2018-06-06	Not applicable

Categories

ATC Codes

N01BB54 — Prilocaine, combinations

• N01BB — Amides
• N01B — ANESTHETICS, LOCAL
• N01 — ANESTHETICS
• N — NERVOUS SYSTEM

N01BB04 — Prilocaine

• N01BB — Amides
• N01B — ANESTHETICS, LOCAL
• N01 — ANESTHETICS
• N — NERVOUS SYSTEM

Drug Categories

• Amides
• Amines
• Anesthetics
• Anesthetics, Local
• Anilides
• Aniline Compounds
• Central Nervous System Agents
• Central Nervous System Depressants
• Local Anesthesia
• Local Anesthetics (Amide)
• Methemoglobinemia Associated Agents
• Nervous System
• Peripheral Nervous System Agents
• Sensory System Agents

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Alpha amino acid amides

Alternative Parents

Alanine and derivatives / Anilides / N-arylamides / Toluenes / Secondary carboxylic acid amides / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds

Substituents

Alanine or derivatives / Alpha-amino acid amide / Amine / Anilide / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxamide group / Hydrocarbon derivative / Monocyclic benzene moiety

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

monocarboxylic acid amide, amino acid amide (CHEBI:8404)

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

046O35D44R

CAS number

721-50-6

InChI Key

MVFGUOIZUNYYSO-UHFFFAOYSA-N

InChI

InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)

IUPAC Name

N-(2-methylphenyl)-2-(propylamino)propanamide

SMILES

CCCNC(C)C(=O)NC1=CC=CC=C1C

References

Synthesis Reference

US3160662

General References

1. DailyMed: Prilocaine Hydrochloride Subcutaneous Injection [Link]

External Links

Human Metabolome Database

HMDB0014888

KEGG Drug

D00553

KEGG Compound

C07531

PubChem Compound

4906

PubChem Substance

46505066

ChemSpider

4737

BindingDB

50225477

RxNav

8686

ChEBI

8404

ChEMBL

CHEMBL1194

Therapeutic Targets Database

DAP000511

PharmGKB

PA451101

Wikipedia

Prilocaine

MSDS

Download (73.4 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Treatment	Anesthesia therapy / Anesthetics Adverse Reaction	1
4	Completed	Not Available	Haemorrhoids / Peri-anal Fistulas	1
4	Completed	Other	Forehead Rhytides / Forehead Wrinkles	1
4	Completed	Other	Periodontal Disease	1
4	Completed	Prevention	Improving Quality of Life	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

• APP Pharmaceuticals
• Astra Pharma Inc.
• AstraZeneca Inc.
• DENTSPLY International
• Diversified Healthcare Services Inc.
• E. Fougera and Co.
• Hi Tech Pharmacal Co. Inc.
• Medisca Inc.
• Nycomed Inc.
• Physicians Total Care Inc.
• Preferred Pharmaceuticals Inc.
• Recipharm AB
• Sandoz
• Tolmar Inc.

Dosage Forms

Form	Route	Strength
Solution	Infiltration
Solution	Infiltration	40 mg / mL
Injection		2 %
Injection, solution	Submucosal
Injection, solution	Parenteral
Injection	Buccal
Injection, solution	Dental	40 mg/1mL
Injection, solution	Submucosal	40 mg/1mL
Cream; kit; tablet, film coated	Oral; Topical
Cream; injection, suspension; kit	Intra-articular; Intramuscular; Topical
Cream; kit	Topical
Ointment	Topical
Cream; gel; kit	Topical
Cream	Cutaneous
Cream	Occlusive dressing technique
Patch	Cutaneous
Plaster	Topical
Patch	Transdermal
Spray	Cutaneous
Kit	Oral; Topical
Kit	Intravenous; Topical
Cream	Topical
Solution	Topical
Gel	Topical
Gel	Dental
Gel	Periodontal
Solution	Subcutaneous
Solution	Infiltration	40 mg
Solution	Infiltration	4000000 mg
Solution	Parenteral
Solution	Parenteral	72 mg
Cream; kit; patch	Cutaneous; Topical
Patch	Topical
Powder	Not applicable	1 g/1g
Injection, solution	Subcutaneous	40 mg/1mL
Injection, solution	Subcutaneous
Capsule; cream; kit	Oral; Topical
Injection, solution		2 %
Injection, solution
Spray	Topical
Cream	Topical	2.5 %w/w
Injection
Injection, solution	Parenteral	2 %
Injection, solution	Intrathecal	20.00 mg/ml
Cream
Injection	Intramuscular	54 mg/54mg
Kit	Topical

Prices

Unit description	Cost	Unit
Prilocaine hcl powder	3.98USD	g

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US6031007	No	2000-02-29	2017-04-01

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	37-38 °C	PhysProp
boiling point (°C)	159-162 °C at 1.00E-01 mm Hg	PhysProp
water solubility	541 mg/L	Not Available
logP	2.11	HANSCH,C ET AL. (1995)

Predicted Properties

Property	Value	Source
Water Solubility	0.326 mg/mL	ALOGPS
logP	1.87	ALOGPS
logP	2.68	Chemaxon
logS	-2.8	ALOGPS
pKa (Strongest Acidic)	13.51	Chemaxon
pKa (Strongest Basic)	8.82	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	2	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	41.13 Å2	Chemaxon
Rotatable Bond Count	5	Chemaxon
Refractivity	67.86 m3·mol-1	Chemaxon
Polarizability	25.98 Å3	Chemaxon
Number of Rings	1	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9557
Blood Brain Barrier	+	0.9285
Caco-2 permeable	+	0.7888
P-glycoprotein substrate	Substrate	0.6968
P-glycoprotein inhibitor I	Non-inhibitor	0.8019
P-glycoprotein inhibitor II	Non-inhibitor	0.9165
Renal organic cation transporter	Non-inhibitor	0.895
CYP450 2C9 substrate	Non-substrate	0.7803
CYP450 2D6 substrate	Non-substrate	0.5124
CYP450 3A4 substrate	Non-substrate	0.5253
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.907
CYP450 2D6 inhibitor	Non-inhibitor	0.9232
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Non-inhibitor	0.8309
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.6298
Ames test	Non AMES toxic	0.7941
Carcinogenicity	Non-carcinogens	0.6653
Biodegradation	Not ready biodegradable	0.9577
Rat acute toxicity	2.1374 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9676
hERG inhibition (predictor II)	Non-inhibitor	0.8577

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Download (8.45 KB)

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-0a4i-9800000000-c7980348fde318ec4477
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	splash10-00di-1390000000-c8416e476741832b2637
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	splash10-00di-0290000000-ecb70add14abedae843c
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	splash10-00di-0290000000-44d4259708c3f68cf9fa
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-000i-9010000000-62668ab56142315d25c7
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-000i-9000000000-b24ca970640547e77f45
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-000i-9000000000-fa235236a550137d65ac
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-000i-9000000000-c5326a5261240ae38b1e
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-000i-9000000000-6c794305d6cd738a7fa3
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-000i-9000000000-ee81ed4cf795affc96e8
MS/MS Spectrum - , positive	LC-MS/MS	splash10-00di-0290000000-ecb70add14abedae843c
MS/MS Spectrum - , positive	LC-MS/MS	splash10-00di-0290000000-44d4259708c3f68cf9fa
MS/MS Spectrum - , positive	LC-MS/MS	splash10-00di-1390000000-c8416e476741832b2637
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-052r-9320000000-e1d7f89efd1442b6a749
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-066r-1980000000-fd228a0d6e0bf1ebbcd9
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0a4i-9500000000-14aaa86a8736f2ecc987
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0a4i-5900000000-c69fa86ca36104334196
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0a4l-9100000000-11928bf1e86745cf11e9
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-053u-4900000000-e65b42561f0d864943a4
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	163.385515	predicted	DarkChem Lite v0.1.0
[M-H]-	151.50673	predicted	DeepCCS 1.0 (2019)
[M+H]+	164.051615	predicted	DarkChem Lite v0.1.0
[M+H]+	153.86473	predicted	DeepCCS 1.0 (2019)
[M+Na]+	163.439915	predicted	DarkChem Lite v0.1.0
[M+Na]+	160.91217	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Sodium channel protein type 5 subunit alpha

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inhibitor

General Function

Voltage-gated sodium channel activity involved in sa node cell action potential

Specific Function

This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...

Gene Name

SCN5A

Uniprot ID

Q14524

Uniprot Name

Sodium channel protein type 5 subunit alpha

Molecular Weight

226937.475 Da

References

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55